The IL-2/IL-15 receptor systems: targets for immunotherapy

J Clin Immunol. 2002 Mar;22(2):51-6. doi: 10.1023/a:1014416616687.

Abstract

Although interleukin-2 (IL-2) and -15 (IL-15) share two receptor subunits and many functions, at times they provide contrasting contributions to T-cell-mediated immune responses. IL-2, through its pivitol role in activation-induced cell death (AICD), is involved in peripheral tolerance through the elimination of self-reactive T cells. In contrast, in general IL-15 manifests antiapoptotic actions and inhibits IL-2-mediated AICD. IL-15 stimulates persistence of memory phenotype CD8+ T cells, whereas IL-2 inhibits their expression. Humanized monoclonal antibodies that recognize IL-2Ra, the private receptor for IL-2, are being employed to inhibit allograft rejection and to treat T-cell leukemia/lymphoma. Therapies directed toward inhibiting the actions of the inflammatory cytokine, IL-15, are proposed for an array of autoimmune disorders as well as diseases associated with the retrovirus human T-cell lymphotrophic virus 1.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use
  • Autoimmune Diseases / therapy
  • Humans
  • Immunotherapy*
  • Interleukin-15 / immunology
  • Interleukin-15 / metabolism
  • Interleukin-2 / immunology
  • Interleukin-2 / metabolism
  • Receptors, Interleukin-15
  • Receptors, Interleukin-2 / immunology*
  • Receptors, Interleukin-2 / metabolism
  • T-Lymphocytes / immunology

Substances

  • Antibodies, Monoclonal
  • IL15RA protein, human
  • Interleukin-15
  • Interleukin-2
  • Receptors, Interleukin-15
  • Receptors, Interleukin-2